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HIV transmissionIn non-human primate models of AIDS, attenuated lentiviruses provide the most reliable protection from
challenge with pathogenic virus but the extent to which the vaccine virus replicates after challenge is unclear.
At 7 and 14 days after vaginal challenge with pathogenic SIVmac239, plasma SIVenv RNA levels were
signiﬁcantly lower in female macaques immunized 6 months earlier with live, attenuated SHIV89.6
compared to unimmunized control animals. In 2 SHIV-immunized, unprotected macaques SIV replication
produced moderate-level plasma viremia with dissemination of challenge virus to all tissues on day 14 after
challenge. In protected, SHIV-immunized monkeys, SIV replication was controlled in all tissues, from the day
of challenge through 14 days post-challenge. Further, in CD8+ T cell-depleted SHIV-immunized animals, SIV
replication and dissemination were more rapid than in control animals. These ﬁndings suggest that
replication of a pathogenic AIDS virus can be controlled at the site of mucosal inoculation by live-attenuated
lentivirus immunization.
© 2009 Elsevier Inc. All rights reserved.Introduction
HIV is a sexually transmitted disease and a vaccine that can stop
HIV transmission offers the best opportunity to stop the AIDS
pandemic. In the simian immunodeﬁciency virus mac (SIVmac)
rhesus macaquemodel of HIV infection, attenuated lentivirus vaccines
have consistently provided the most effective protection against
systemic and mucosal challenge with pathogenic SIV (Abel et al.,
2003; Abel et al., 2004; Almond et al., 1995; Miller et al., 1997). The
degree of protection conferred by an attenuated lentivirus vaccine is
related to the ability of the vaccine virus to replicate in the host
(Lohman et al., 1994) and highly attenuated viruses do not replicate
sufﬁciently to generate a protective immune response (Ruprecht,
1999; Busch et al., 2005). Although reversion to virulence and
integration-based carcinogenesis preclude the use of attenuated
lentivirus vaccines in humans, identifying the mechanisms by which
attenuated lentiviruses confer protectionwill be useful for developing
other vaccine approaches.
The route of immunizationwith nonpathogenic SHIV 89.6 does not
alter the level of protection, as either vaginal, intranasal or intra-Ave., Davis, CA 95616. Fax: +1
l rights reserved.venous inoculation of SHIV 89.6 produces protection from uncon-
trolled virus replication after vaginal SIV challenge in about 60% of the
immunized animals (Abel et al., 2003). The similar level of protection
following mucosal and systemic inoculation of SHIV is likely due to
SIV-speciﬁc T cell responses in the vagina that are primed and
maintained by vaccine virus replication in the genital tract during the
6–8 months of systemic SHIV infection, even after IV inoculation
(Genescà et al., 2008b). Thus in this model, the immunizing virus
establishes a persistent, disseminated infection and antiviral immune
responses are distributed to all tissues.
We recently established a correlation between protection from
uncontrolled viral replication after vaginal SIV challenge and the
presence of CD8+ T cell responses in the vagina (Genesca, McChesney,
and Miller, 2009). The SHIV-induced, antiviral CD8+ T cell response is
characterized by cytolytic T cells in the vagina of 60% of immunized
animals, but these antiviral T cell responses aremuchmore inconsistent
in cervix and other tissues (Genescà et al., 2008a). CD8+ Tcell depletion
at the time of SIV challenge abrogates the protective effect of SHIV
immunization conﬁrming the critical role of CD8+Tcells in the observed
protection (Genescà et al., 2008b).Unexpectedly, after SIV challenge, the
protective antiviral Tcell response does not signiﬁcantly expand in blood
or tissues, except in the vagina (Genescà et al., 2008b).
While the nature of immunologic responses to infection with atte-
nuated SHIV is being elucidated, characterizing the viral populations
Fig. 1. Plasma vRNA levels in naive control and SHIV-immunized monkeys after vaginal
challengewith SIVmac239. Plasma SIVgag concentration (copies/ml) at (A) 7 days and (B)
14daysp.c. PlasmaSIVenv concentration (copies/ml) at (C) 7days and (D) 14daysp.c. Each
symbol represents the result for an individual animal. The horizontal line indicates the
mean plasma vRNA level in each animal group. The p values were calculated using a
unpaired one-tailed T-test.
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taken. In fact, in other attenuated lentivirus vaccinemodels it is unclear
if “vaccine failure” is due to replicationof the vaccinevirus, the challenge
virus, or both (Almond et al.,1995; Berry et al., 2008; Kwoﬁe et al., 2002;
Mackay et al., 2004; Reynolds et al., 2008; Rose et al.,1995; Shibata et al.,
1997; Silverstein et al., 2000b; Ui et al., 1999; Wakrim et al., 1996).
Recombination between vaccine and challenge virus (Gundlach et al.,
2000; Reynolds et al., 2008), persistence of vaccine virus after challenge
(Mackay et al., 2004; Silverstein et al., 2000a) or persistence of both
vaccine and challenge virus (Khatissian et al., 2001) have been reported.
The assays commonly used to assess levels of viral replication do not
distinguish between vaccine and challenge virus. Further, the relative
contribution of the vaccine and challenge viruses to vaccine failure, the
extent of SIV dissemination and the sites of SIV replication after
challenge of SHIV89.6 immunizedmonkeys are not known. As infection
of CD4+Tcells byan “attenuated”virusvaccine coulddeplete target cells
in tissues interfering with challenge virus replication, it is critical to
understand the extent to which vaccine virus contributes to uncon-
trolled virus replication after pathogenic virus challenge. Thus, to better
understand the anatomic sites of vaccineand challenge virus replication,
we sought to determine the extent of SIV dissemination and replication
in tissues of SHIV-immunized animals after challenge.
Results
The relative contribution of the vaccine and challenge viruses to plasma
viremia after vaginal SIVmac239 challenge
The overall design and challenge outcome of this study based on
plasma vRNA levels have been recently reported (Genescà et al.,
2008a). Brieﬂy, 26 animals previously infected with SHIV89.6 for
6–8 months were challenged vaginally with SIVmac239 along with 21
unvaccinated control animals that received only challenge virus. The
SHIV-immunized animals were necropsied at the time of challenge
(n=9), 3 days p.c. (n=3), 7 days p.c. (n=6), and 14 days p.c.
(n=12), while the unvaccinated control animals were necropsied at
3 days p.c. (n=3), 7 days p.c. (n=9), and 14 days p.c. (n=9). We
have previously shown that approximately 60% SHIV-immunized
rhesus macaques maintain plasma vRNA levels below 104 copies/ml
and normal CD4+ T cell numbers in blood for 6 months after
intravaginal challenge with SIV (Abel et al., 2003; Busch et al., 2005;
Genesca et al., 2007). These animals are deﬁned as “protected”.
However in SHIV-immunized rhesus macaques that have plasma
vRNA levels above 104 copies/ml at any time during the 6-month
observation period after vaginal SIVmac239 challenge, CD4+ T cell
numbers steadily decline and these animals are deﬁned as “unpro-
tected” (Abel et al., 2003; Busch et al., 2005; Genesca et al., 2007).
As previously reported using the SIVpol-speciﬁc bDNA assay to
measure viral load (Genescà et al., 2008a), the mean plasma gag vRNA
level of the unimmunized control animals was signiﬁcantly higher than
the mean plasma gag vRNA level of the SHIV-immunized animals at
both 7 and 14 days p.c. using an SIVgag RT-PCR assay (Figs. 1A and B).
Of note, 2 of the SHIV-immunized animals had plasma SIVgag RNA
levels N104 copies/ml at 14 days PI, thus these 2 animals are deﬁned
as unprotected and would be expected to have steadily declining
numbers of CD4+ T cells (Abel et al., 2003; Busch et al., 2005; Genesca
et al., 2007).
To determine if the vaccine or challenge virus was the source of the
plasma vRNA, plasma SIVenv vRNA levels were measured by RT-PCR
(Fig. 1). At 7 days p.c. SIVenv RNA was detected in plasma of 10 of 18
SHIV-naïve control animals (ranging from 102 to N105 vRNA copies/ml),
but SIVenv RNAwas detected in only 4 of 18 SHIV-immunized monkeys
(less than 103 vRNA copies/ml). The difference in the mean plasma
SIVenvRNA level of the2 groupswas statistically signiﬁcant (Figs.1C and
D). By day 14 p.c. all 9 of the control animals had high SIVenv vRNA in
plasma (105–108 vRNA copies/ml), but only 5 of 12 SHIV-immunizedmonkeyshadmoderate plasmaSIVenvRNA+(103–106 vRNAcopies/ml),
and the mean plasma SIVenv RNA levels of the 2 groups were
signiﬁcantly different (Figs. 1C and D). As with SIVgag RNA, the plasma
SIVenvRNA levels in the 2 “unprotected” SHIV-immunized animalswere
N104 copies/ml at 14 days PI.
SIVgag and SIVenv RNA levels in the tissues of naïve control animals after
vaginal SIV challenge
The RT-PCR assay was used to quantify the number of SIVgag copies
in a tissue sample and results are reported using vRNA copies/μg tissue
RNA. We classiﬁed samples with b104 vRNA copies/μg tissue RNA to
have low levels of vRNA; samples with 104–106 vRNA copies/μg tissue
RNA to have moderate levels of vRNA; and samples with N106 vRNA
copies/μg tissue RNA to have high levels of vRNA.
SIVgag RNA was not detected in any tissue sample collected from
the 3 control animals necropsied at 3 days p.c., (Fig. 2). At 7 days p.c.
SIVgag RNA was detected in at least one tissue collected from 7 of 9
control animals (Fig. 2). Of these 7 vRNA+ animals, moderate SIVgag
RNA levels were found inmultiple tissues of 5 animals while 2 animals
had only a low level of SIVgag RNA in one tissue. By day 14 after
vaginal SIVmac239 inoculation, moderate to high levels of SIVgag
vRNA were detected in the tissues of all 9 unimmunized control
animals necropsied (Fig. 2).
Among the 7 SIVgag RNA+ control animals at day 7 PC after vaginal
SIV challenge, the genital lymph nodes had the highest SIVgag RNA
levels in 2 animals, and in the remaining 5 animals the tissue with the
highest SIVgag RNA levels was unique to each animal (Fig. 2). At 7 days
p.c., the lowest SIVgag RNA levels in the control animals as a group
were in the genital tract (cervix, vagina) (Fig. 2). Among the 9 control
animals necropised at day 14 p.c., the highest levels of SIVgag RNA
were seen in the colon and mesenteric lymph nodes draining the
intestinal tract, with intermediate vRNA levels in the systemic
lymphoid tissues (axillary lymph node and spleen), and the lowest
Fig. 2. SIV SIVgag RNA levels in tissues of naïve control and SHIV-immunized monkeys after vaginal SIVmac239challenge. (A) naïve control animals (SIVgag RNA copies/μg tissue
RNA) and (B) SHIV-immunized animals (SIVgag RNA copies/μg tissue RNA); CD8+ lymphocyte-depleted, SHIV-immunized animals are indicated by a solid horizontal line under the
animal numbers at the far right of the x-axis. Anatomic sites are denoted as follows: genital tract (closed red symbols), genital lymph nodes (open red symbols), peripheral lymphoid
tissues (closed blue symbols), and intestinal tract/mesenteric LN (green symbols). The vRNA levels for the indicated tissues are displayed vertically above the animal numbers along
the x-axis. The animals are grouped by the timing of necropsy after vaginal SIVmac239 challenge, as indicated by the brackets under the animal numbers. The horizontal dotted line
indicates the limit of quantiﬁcation for this assay and represents the cutoff value for designating positive samples.
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(cervix, vagina, obturator lymph node, inguinal lymph node, and iliac
lymph node) (Fig. 2).
In the unimmunized control animals, the SIVenv RNA levels in
every tissue samplewere essentially identical to the SIVgag RNA levels
in the matched sample (Fig. 3). Tissue samples from animals
necropsied at 3 days p.c. were uniformly negative for SIVenv. By
7 days p.c. SIVenv RNAwas detected in multiple tissue samples from 7
of 9 unimmunized control animals (Fig. 3). Of these 7 SIVenv RNA+
control animals, low to moderate SIVenv RNA levels were found in
multiple tissues of 5 animals and 2 animals had low levels of SIVenv
RNA in multiple tissues. At 7 days p.c., the lowest SIVenv RNA levels in
the SIV control animals were generally in the genital tract (cervix,
vagina) (Fig. 3). By day 14 after vaginal SIVmac239 inoculation,
moderate to high of SIVenv RNA levels (SIV copies/μg tissue RNA)were
detected in all tissue samples collected from all 9 naïve control
animals. At day 14 p.c., the highest SIVenv RNA levels were in the
mesenteric lymph nodes of 8 animals and the lowest SIVenv RNA
levels were in the genital tract (cervix, vagina,) (Fig. 3).SIVgag and SIVenv RNA levels in tissues of SHIV-immunized animals
before, and after, vaginal SIV challenge
Prior to SIV challenge, low levels of SIVpol RNA representing
residual SHIV replication were detected using a bDNA assay in tissues
of 6 of 9 SHIV-immunized animals and the colon was most
consistently SIV RNA positive tissue in these animals (Genescà et al.,
2008b). After vaginal SIV challenge, the anatomic distribution of
SIVgag RNA in tissues of SHIV-immunized animals was very distinct
from the distribution of SIVgag RNA in tissues of the SIV control
animals (Fig. 2). In the SHIV-immunized animals that had SIVgag RNA
in tissues at days 3 and 7 p.c., the tissues with the highest levels of
SIVgag RNA were consistently in the vagina, cervix or genital lymph
nodes (Fig. 2). Ten of 12 SHIV-immunized animals necropsied at day
14 p.c. controlled virus replication, and 8 of these animals had
detectable SIVgag RNA in tissues. In these 8 animals, the highest levels
of SIVgag RNAwere in the mesenteric LN of 2 of animals, in the spleen
of 2 animals and in the inguinal LN, colon or axillary LN of the
remaining 4 animals (Fig. 2). However in the two SHIV-immunized
Fig. 3. SIV SIVenv RNA levels in tissues of SHIV-immunized monkeys and naïve monkeys after vaginal SIVmac239challenge. (A) naïve control animals (SIVenv RNA copies/μg tissue
RNA and (B) SHIV-immunized animals (SIVenv RNA copies/μg tissue RNA; CD8+ lymphocyte-depleted SHIV-immunized animals are indicated by a solid horizontal line under the
animal numbers at the far right of the x-axis. The ﬁgure organization is similar to Fig. 2.
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the levels of SIVgag RNA were highest in the colon and mesenteric
lymph nodes at day 14 p.c. (Fig. 2).
After vaginal SIV challenge, the anatomic distribution of SIVenv RNA
and SIVgag RNA in tissues of SHIV-immunized animals was similar
(Fig. 3), and very distinct from the distribution of SIVenv RNA in tissues
of the control animals. Thus, at days 3 and 7p.c, the genital lymphnodes,
vagina/cervix or colon had the highest levels of SIVenv (SIVenv RNA
copies/μg tissue RNA) in the 7 SHIV-immunized animals that had SIVenv
RNA in tissues (Fig. 3). In 8 of the 10 SHIV-immunized animals
necropsied at day 14 that controlled virus replication (Fig. 3) the highest
levels of SIVenvRNAwere found in the genital LN, the vagina or cervix. In
the 2 remainingprotected animals the highest levels of SIVenvRNAwere
in the mesenteric LN (Fig. 5C). Similarly, in the two unprotected, SHIV-
immunized animals (28843, 32330) with relatively uncontrolled viral
replication at day 14 p.c., the SIVenv levels were highest in the
mesenteric lymph nodes (Fig. 3).
SHIV-immunized animals have no signiﬁcant increase in tissue SIVgag
and SIVenv RNA levels after SIV challenge
To assess the kinetics of viral replication in tissues of control and
SHIV-immunized animals, themean SIVgag and SIVenvRNA levels in thetissues of each immunized and control animal was calculated and the
groupmeanswere compared. As expected, themeanSIVgagRNA level in
tissues of the unimmunized control animals was signiﬁcantly higher on
day 14 p.c. compared to day 7 p.c. (pb0.0001, one-tailed T-test, data not
shown). As with SIVgag RNA, the mean level of SIVenv RNA in tissues of
theunimmunized control animalswas signiﬁcantly higher onday 14 p.c.
compared to day 7 p.c. (pb0.0001, one-tailed T-test, data not shown).
In marked contrast the mean SIVgag RNA levels in the tissues of the
SHIV-immunized animals decreased, although not signiﬁcantly, from
day 7 p.c. compared to day 14 p.c. (data not shown). Thus the im-
munized animals controlled viral replication in all tissues after vaginal
SIV challenge. Further, the mean tissue SIVenv RNA level of the SHIV-
immunized animals did not increase from day 7 p.c. to day 14 p.c. (data
not shown). Thus although the 2 unprotected, SHIV-immunized
animals were included in the analysis, the SHIV-immunized animals
controlled SIV replication in all tissues after vaginal SIV challenge.
SHIV-immunized animals have signiﬁcantly lower total body SIVgag and
SIVenv RNA levels after vaginal SIV challenge than control animals
To assess the level of protection in SHIV-immunized animals, the
mean SIVgag and SIVenv RNA levels in the tissues of each immunized
and control animalwas calculated and thegroupmeanswere compared.
Fig. 4. HIV HIVenv RNA levels in tissues of SHIV-immunized monkeys after vaginal SIVmac239challenge. (A) SHIV-immunized animals (HIVenv RNA copies/μg tissue RNA; CD8+
lymphocyte-depleted SHIV-immunized animals are indicated by a solid horizontal line under the animal numbers at the far right of the x-axis. The ﬁgure organization is similar to Fig. 2.
Fig. 5. Plasma vRNA levels in SHIV-immunized monkeys, SHIV-immunized, CD8+
lymphocyte-depleted monkeys and naive control monkeys after vaginal challenge with
SIVmac239. Comparison of plasma SIVgag concentration (copies/ml) at (A) 7 days and (B)
14days p.c.; andplasmaSIVenv concentration (copies/ml) at (C) 7days and (D) 14days p.c.
in naïve control and CD8+ T cell-depleted SHIV-immunized animals. Comparison of
plasma HIVenv concentration (copies/ml) in SHIV-immunized and CD8+ T cell-depleted,
SHIV-immunized animals at (E) 7 days and (F) 14 days p.c. Each symbol represents the
result for an individual animal. Thehorizontal line indicates themeanplasmavRNA level in
each animal group. P values were generated with an unpaired one-tailed T-test.
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tissue of the control animals compared to SHIV-immunized animals
(data not shown) and at day 14 p.c. the mean SIVgag RNA level in every
tissue of the control animalswas signiﬁcantly higher compared to SHIV-
immunized animals (pb0.0001, One-way Anova, data not shown).
Further when the mean SIVgag RNA in all of an animal's tissue samples
was calculated to produce a total body SIVgag RNA level for each animal,
we found that although not signiﬁcantly lower, by day 7 p.c. the mean
total body SIVgagRNA level of thevaccinated animal tissues tended to be
lower (p=0.065, one-tailed T-test) than the mean total body SIVgag
RNA level of control animals (data not shown). By day 14 p.c., the virus
was fully disseminated in the control animals and the mean total body
SIVgag RNA level of the SHIV-immunized animals was signiﬁcantly
lower than themean total body SIVgag RNA level in the control animals
(pb0.0001, one-tailed T-test, data not shown).
Like SIVgag, at day 7 p.c. there was a trend toward higher mean
SIVenv RNA level in every tissue of the control animals compared to
SHIV-immunized animals (data not shown) and at day 14 p.c. the mean
SIVenv RNA level in every tissue of the control animals was signiﬁcantly
higher compared to SHIV-immunized animals (pb0.0001, one-way
Anova, data not shown). Further when the mean SIVenv RNA in an
animal's tissue samples was calculated to produce a total body SIVenv
RNA level for each animal, we found that by day 7 p.c. the mean total
body SIVenv RNA level of the vaccinated animals was signiﬁcantly lower
(p=0.037) than the mean total body SIVenv RNA level of control
animals (data not shown). By day 14 p.c., the virus was fully
disseminated in the control animals and the mean total body SIVenv
RNA level of the SHIV-immunized animals was signiﬁcantly lower than
the mean total body SIVenv RNA level in the SIV control animals
(pb0.0001, one-tailed T-test, data not shown).
HIVenv RNA levels in tissues of SHIV-immunized animals before,
and after, after vaginal SIV challenge
To determine the level of SHIV virus replication in the tissues of
the SHIV-immunized animals, HIVenv RNA levels were measured by
RT-PCR. As expected, HIVenv RNA was undetectable in all tissue
samples collected from the unimmunized control animals at all time
points (data not shown). On the day of challenge, HIVenv RNA was
detected in the tissues of 5 of 9 SHIV-immunized animals with high
HIVenv RNA in the tissue samples of 1 of the 9 SHIV-immunized
animals, and low tomoderate HIVenv RNA levels in tissues of 4 of the 9
immunized animals (Fig. 4). At 3 days p.c., 3 of 3 SHIV-immunized
265M. Stone et al. / Virology 392 (2009) 260–270animals had low tomoderate HIVenv RNA levels inmost tissues (Fig. 4).
At 7 days p.c., moderate to low HIVenv RNA levels were detected in all 6
animals, and at 14 days p.c. 10 of 12 animals had moderate to low
HIVenv RNA levels in at least one tissue (Fig. 4). In most of the HIVenv
RNA+ animals necropsied from the day 0 to day 14 p.c, the lymph nodes
had the highest HIVenv RNA levels among the tissues tested, but there
were no signiﬁcant differences in HIVenv RNA levels among the tissues.
Relative levels of SIVgag, SIVenv and HIVenv RNA in blood of
SHIV-immunized, CD8+ T cell-depleted animals after vaginal
SIV challenge
The protective effect of SHIV-immunization was eliminated in 5
animals after pharmacological depletion of CD8+ T cells (Fig. 5). Thus,
themeanplasma SIVgag RNA level of the SHIV-immunized, CD8+ Tcell-
depleted animals at both 7 and 14 days p.c was signiﬁcantly higher than
the mean SIVgag RNA level of the SHIV-immunized animals (data not
shown). In fact at 7 days p.c., the mean plasma SIVgag RNA level of the
SHIV-immunized, CD8+Tcell-depleted animalswas signiﬁcantly higher
than themeanplasma SIVgag RNA level of the control animals (Fig. 5A).
SIVenv RNA was readily detectable in the plasma of all the SHIV-
immunized CD8+ T cell-depleted animals at days 7 and 14 p.c. (Figs. 5CFig. 6. Comparison of SIVgag RNA copies/μg tissue RNA in tissues at 14 days p.c. among SHIV-im
extent to which the relative levels of virus replication in speciﬁc tissues were altered by the SH
obturator LN, inguinal LN, iliac LN, axillary LN, spleen, mesenteric LN, and colon. Statistical diffand D). At day 7, all 5 of the CD8+ depleted animals had SIVenv RNA in
plasma compared to only 10 of 14 control animals. Further, at 7 days p.c.
the mean plasma SIVenv RNA level in the CD8+ T cell-depleted animals
was signiﬁcantly higher than the mean plasma SIVenv RNA level of the
control animals (Fig. 5C). By day 14 p.c. plasma SIVgag and SIVenv RNA
levels in control and SHIV-immunized CD8+ T cell-depleted animals
were similar. All of 5 of the CD8+ depleted animals had HIVenv RNA in
plasma at both 7 and 14 days p.c. (Figs. 5E and F). Further, at both time
points the mean plasma HIVenv RNA levels in the CD8+ T cell-depleted
animals were signiﬁcantly higher than in the T cell intact SHIV-
immunized animals. The high plasma vRNA levels at 7 days p.c.
demonstrate that, compared to unimmunized control animals, SIV
replication and dissemination were signiﬁcantly enhanced in SHIV-
immunized animals that were depleted of CD8+ Tcells on the day of SIV
challenge.
Relative levels of SIVgag, SIVenv and HIVenv RNA in tissues of
SHIV-immunized CD8+ T cell-depleted animals after vaginal
SIV challenge
All 5 CD8+ Tcell-depleted animals had uncontrolled viral replication
and high levels of SIVgag RNA in all tissues samples collected at daymunized, SHIV-immunized CD8 depleted, and naïve control monkeys. To determine the
IV immunization, SIVgag vRNA copies/μg tissue RNA are compared in the cervix, vagina,
erences calculated by one-way ANOVAwith Bonferroni's multiple comparison test.
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samples from these animals (Fig. 3). Low to moderate levels of HIVenv
RNA were detected in tissues from 4 of 5 CD8+ depleted animals,
although these levels of HIVenv RNA were considerably lower than the
SIVgag RNA levels measured in the same samples (Fig. 4).
Strikingly, the anatomic pattern of vRNA in the tissues of SHIV-
immunized, CD8+ T cell-depleted animals was unlike that in tissues of
the T cell-intact, SHIV-immunized animals that were necropsied on day
14 after challenge. Thus, 3 of the 5 SHIV-immunized CD8+ T cell-
depleted animals had very high levels of SIVgag and SIVenv RNA (N106
vRNA copies/μg tissue RNA) in the reproductive tract and the other 2
SHIV-immunized CD8+ T cell-depleted animals had very high levels of
SIVgag and SIVenv RNA (N106 vRNA copies/μg tissue RNA) in the genital
lymphnodes (inguinal, axillary and iliac lymphnodes) (Figs. 2B and 3B).
Comparison of SIV replication in tissues of study animals at 14 days p.c.
The relative levels of viral replication (mean number of SIVgag RNA
copies/μg tissue RNA) between tissues of control animals, SHIV-
immunized animals and SHIV-immunized CD8+Tcell-depleted animals
at day 14 p.c. were compared using a one-way ANOVAwith Bonferroni's
multiple comparison test (Fig. 6). In thegenital tract (vaginaand cervix),
the portal of virus entry and initial site of SIV replication after vaginal SIV
inoculation, the SHIV-immunized animals had signiﬁcantly lower levels
of SIVgag than the control animals and the CD8+ T cell-depleted SHIV-
immunized animals (Fig. 6). Strikingly, the CD8+ T cell-depleted SHIV-Fig. 7. Comparison of the density of SIV RNA+ cells in the genital tract and axillary lymph
hybridization. Panels A and C: tissues from control SIV-infected animal at 14 days p.c. Panels B
A and B, vagina, bars indicate 25 μm; Panels C and D, axillary LN, bars indicate 50 μm. Hemimmunized animals had signiﬁcantly higher levels of SIVgag RNA in the
vagina than the unimmunized control monkeys (Fig. 6A). The Taqman
RT-PCR resultswere conﬁrmedby ISH labelingof SIVRNA+cells in tissue
sections (Fig. 7) and quantitative image analysis. Thus, there were sig-
niﬁcantly more SIV RNA+ cells in histologic sections of vagina
(p=0.003, unpaired 2-tailed T-test) but not the axillary LN, of the
SHIV-immunized CD8 T cell-depleted animals compared to the unim-
munized control animals (Fig. 7). This result demonstrates that the
amount of vRNA in the vaginal mucosa of the T cell-depleted monkeys
was higher than in the control animals.
Among the tissues that become infected as virus disseminates from
the portal of entry, the lymph nodes that drain the genital tract (iliac,
inguinal and obturator lymph nodes) become infected by lymphatic
dissemination and they are the secondary sites of SIV replication after
vaginal SIV inoculation. The level of virus replication (SIVgag RNA
copies/μg tissue RNA) in the genital lymph nodes of the SHIV-
immunized animals was signiﬁcantly lower than in the matched
samples from control animals and CD8+ T cell-depleted immunized
animals (Figs. 6C–E). Further, among the tissues that become infected by
hematogenous dissemination from the genital lymph nodes and are
tertiary sites of SIV replication after vaginal SIV inoculation, there were
signiﬁcantly lower levels of vRNA in systemic lymphoid tissues (spleen,
axillary lymph nodes) and gut-associated lymphoid tissues (mesenteric
lymph nodes and colon) of the SHIV-immunized animals than in the
same tissues of the control animals and the CD8+ T cell-depleted SHIV-
immunized animals (Figs. 6F–I). Thus the levels of virus replication innode of naïve control and SHIV-immunized CD8+ T cell-depleted animals by in situ
and D: tissues from SHIV-immunized CD8+ Tcell-depleted animal at 14 days p.c. Panels
atoxylin counterstain.
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from the genital tract were similar in the CD8+ T cell-depleted
immunized animals and unimmunized control monkeys.
Discussion
We have previously determined that the protection from uncon-
trolled SIV replication in 60% of rhesus macaques after SHIV89.6
immunization is due to the presence of CD8+ T cells in the vaginal
mucosa of the immunized animals (Genescà et al., 2008a, 2008b).
Further in SHIV-immunized animals that are monitored for 6 months
after SIV challenge, the uncontrolled viral replication that charac-
terizes the unprotected animals does not become apparent until
plasma vRNA levels rise 2–3 months after vaginal SIV challenge (Abel
et al., 2003; Busch et al., 2005; Genesca et al., 2007;Miller et al., 1997).
This strongly suggests that ongoing SIV replication occurs in tissues of
SHIV-immunized, unprotected animals even when little plasma vRNA
is detected. The goal of the present study was to deﬁne the extent of
attenuated SHIV89.6 (vaccine virus) and pathogenic SIV (challenge
virus) replication in the tissues of rhesus macaques immunized with
SHIV89.6 for 6–8 months and then challenged vaginally with
SIVmac239. Based on both SIVgag and SIVenv RNA levels, it was
straightforward to distinguish the immunized animal group from the
control animal group at 7days p.c., because mean plasma and tissue
vRNA levels in the immunized animalswere signiﬁcantly lower than in
the naïve control animals. Thus there is control of viral replication in all
tissues of the SHIV-immunized animals at day 7 after vaginal SIV
challenge. Control of virus replication across all of the anatomic sites
suggests that either the infectionwas contained near the site of vaginal
inoculation by SIV-speciﬁc CD8+ T cells or that virus replication was
efﬁciently controlled by systemic SIV-speciﬁc CD8+ T cell responses
after the virus disseminated to all tissues. The former explanation
seems more likely because as we recently reported (Genescà et al.,
2008a), after challenge, SIV-speciﬁc CD8+ T cell responses in the
vagina expanded but there was no detectable expansion of T cell
responses in any other anatomic site. As expansion of SIV-speciﬁc T
cells is presumably antigen-driven, the combined results of the
virologic and immunologic analyses are most consistent with the
conclusion that there is little systemic dissemination and replication of
SIV in the SHIV-immunized and protected animals.
The ability of SHIV89.6 to induce protective CD8+ T cell responses
in the genital tract seems to be related to its pattern of persistent
replication. Although SHIV89.6 did not replicate to high levels in any
tissue at 6–8 months post-immunization, HIVenv RNA produced by
SHIV89.6 replication was consistently found in the reproductive tract
and draining lymph nodes on the day of challenge and at 7 and 14 days
after vaginal SIV challenge. The persistence of SHIV replication likely
explains the presence of antiviral T cells in the vaginal mucosa of the
SHIV-immunized animals on the day of challenge (Genescà et al.,
2008b). However the low-level residual SHIV89.6 replication that was
detected on the day of challenge in tissues of all the immunized
animals did not increase after vaginal SIV challenge. This was also the
case in the 2 unprotected, SHIV-immunized animals in which SIVgag
and SIVenv RNA levels were relatively high in the plasma and tissues at
14 days p.c. while HIVenv RNA levels were in the same low range
found in the SHIV-immunized animals necropsied on the day of SIV
challenge. Thus SHIV89.6 replication did not signiﬁcantly contribute
to uncontrolled viral replication in the immunized but unprotected
monkeys after vaginal SIVmac239 challenge.
In our previous studies approximately 60% of SHIV-immunized
animals control challenge virus replication so that plasma vRNA levels
never exceed 104 copies/ml over a 6-month observation period.
Although the current study involved only a 14-day observation period
after vaginal SIV challenge, some of the SHIV-immunized animals
controlled virus replication and some did not. It was not possible to
distinguish protected from unprotected animals among the SHIV-immunized group at day 7 p.c. However by 14 days p.c., SIV replication
had increased dramatically in 2 of the 10 SHIV-immunized animals and
these2 animals (28843, 32330)were consideredunprotected. This is the
same proportion of animals that were unprotected at 14 days p.c. in our
previous SHIV immunization SIV challenge studies (Abel et al., 2003).
Further, although the levels of viral replication were reduced in these 2
unprotected SHIV-immunized animals, compared to unimmunized con-
trol animals the anatomic distribution of viral replication in these 2
animals was similar to the control animals.
Fourteen days after vaginal SIV challenge, the anatomic distribu-
tion of challenge virus in tissues among the SHIV-immunized,
protected animals was distinct from the distribution of challenge
virus in the unimmunized control animals that had relatively
uncontrolled viral replication (Figs. 2, 3 and 6). In the control animals,
the highest levels of vRNA were in the mesenteric lymph node and
colon, the lowest in the reproductive tract and draining lymph nodes
with intermediate SIVenv levels in the systemic lymph nodes. At day
14 p.c. in the SHIV-immunized animals that controlled SIV replication,
the highest levels of SIVenv RNAwere found in the genital mucosa and
genital lymph nodes. This result supports the conclusion that SIV
dissemination was limited in the SHIV-immunized protected animals.
In marked contrast, the relative levels of SIVenv RNA among the
tissues of SHIV-immunized, unprotected animals and the unimmu-
nized control animals were similar at day 14 p.c. Thus, 14 days after
vaginal SIV challenge, the SIVenv RNA levels were highest in the
mesenteric LNs of the unimmunized control animals and the SHIV-
immunized animals that did not control viral replication. The SIVenv
RNA in the mesenteric lymph nodes is convincing evidence that SIV
rapidly disseminates and replicates in the unprotected SHIV-immu-
nized animals.
At both days 7 and 14 p.c., SIVenv RNA plasma levels were
signiﬁcantly higher in the CD8-depleted SHIV-immunized animals
compared to the CD8+Tcell intact SHIV-immunized animals. This result
conﬁrms our previous conclusion that CD8+ T cells are responsible
for the control of challenge virus replication after vaginal SIV challenge
(Genescà et al., 2008a). The fact that the CD8+ T cell-depleted
SHIV-immunized animals had a signiﬁcantly higher mean plasma
SIVgag RNA level (SIVgag copies/ml plasma) than the unimmunized
control animals at 7 days p.c. indicates that after vaginal inoculation, SIV
replication was enhanced in SHIV-immunized CD8+ T cell-depleted
monkeys compared to control animals. Further at both day 7 and 14 p.c.,
plasma HIVenv RNA levels were signiﬁcantly higher in the CD8+ T cell-
depleted SHIV-immunized animals compared to the HIVenv RNA levels
in T cell intact SHIV-immunized animals, consistent with a loss of
immune control of vaccine virus replication in the CD8-depleted, SHIV-
immunized animals.
Depletion of the CD8+ T cell population altered the anatomic
distribution of viral replication. In the CD8+ T cell-depleted animals,
the highest levels of SIV replication are in the genital tract and
genital lymph nodes and in fact the vRNA levels in these tissues
exceeded those found in the colon and mesenteric LN of control
animals. This very high level of viral replication in the vagina and
genital lymph nodes is unprecedented and suggests that in the
absence of antiviral CD8+ T cells, SIV replication in the genital tract
was enhanced by prior SHIV immunization. The potential to
increase viral replication in SHIV-immunized animals is consistent
with our previous report that SHIV-immunized animals have
numerous SIV-speciﬁc CD4+ T cells in the vaginal mucosa on the
day of challenge (Genescà et al., 2008b). It seems likely that these
CD4+ T cells in the vaginal mucosa of the immunized animals
provide more cellular targets compared to the naïve animals leading
to enhanced local viral replication. Thus an increased number of
infected target cells in the genital tract is the likely source of the
high levels of plasma vRNA seen at 7 days p.c. in the CD8+ T cell-
depleted animals. As this effect was only seen in the genital tract,
the SIV-speciﬁc CD4+ T cells that enhance virus replication in the
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replication, in the other lymphoid tissues. Thus, SHIV-immunized
animals have the potential to support enhanced challenge virus
replication in the genital tract and this potential is realized after SIV
speciﬁc effector CD8+ T cells are eliminated by CD8+ T cell
depletion. It is possible that the higher vRNA levels found in the
plasma and tissues of the CD8-depleted animals was a result of the
high levels of immune activation induced by the administration of
the cM-T807 antibody. However a recent study suggests that the
immune activation that occurs in response to CD8+ T cell depletion
does not contribute to enhanced SIV replication (Okoye et al., 2009).
The results of the CD8+ T cell depletion experiment essentially
eliminate a role for viral interference in the protection we observe in
animals immunized with attenuated SHIV 89.6. If infection of CD4+ T
cells by SHIV89.6 had depleted these critical target cells making them
unavailable to support SIV replication, we would not expect to see
enhanced viral replication in CD8+ T cell-depleted animals relative to
control animals at 7 days p.c. This result demonstrates that viral
replication after challenge results from a balance between SIV
replication in abundant target cells and efﬁcient killing of those
infected target cells by antiviral CD8+ T cells.
Our ﬁndings are similar in some respects to the results reported
when macaques immunized with an attenuated SHIV are challenged
with a closely related pathogenic SHIV; the persistence of the vaccine
virus is a primary correlate of protection from challenge virus
replication and disease progression (Mackay et al., 2004; Silverstein
et al., 2000b). In our system, the attenuated SHIV virus persisted in
tissues until the day of challenge in at least one tissue from 6 of 9
animals examined (Figs. 2 and 3) and (Genescà et al., 2008b) and SHIV
vRNA remained at low but detectable levels after SIV challenge
(Fig. 2). In fact, CD8+ T cells also control replication of the attenuated
SHIV vaccine virus in our model, as demonstrated by the increased
replication of the vaccine virus which contributed moderately to viral
replication in CD8+ depleted monkeys after vaginal SIV challenge
(Fig. 6). However, our conclusion that the attenuated vaccine virus
persists in tissues after pathogenic virus challenge differs from a
report (Berry et al., 2008) that the vaccine virus is undetectable after
pathogenic SIV challenge in macaques immunized with an attenuated
molecular clone of SIVmac251. However, CD8+ T cells do not seem to
play a role in protection in macaques immunized with this attenuated
SIVmac251 (Stebbings et al., 1998).
The present study establishes that in protected SHIV-immunized
monkeys, control of SIV replication extended anatomically from the
genital tract portal of entry to the gut-associated and systemic
lymphoid tissues, and temporally from the day of challenge through
14 days PC. Further, in unprotected, SHIV-immunized monkeys, the
challenge virus is the source of the relatively high levels of vRNA in
tissues and blood, with the highest vRNA levels in mesenteric lymph
node and colon. However after CD8+ T cells were depleted, the SIV
speciﬁc CD4+ T cell responses found in the genital tract of SHIV-
immunized animals (Genescà et al., 2008b) apparently enhanced virus
replication at the portal of entry. As T cell vaccines elicit both CD8+ and
CD4+ T cell responses, the potential for enhanced viral replication, and
perhaps enhanced susceptibility to infection as seen in the STEP trial,
may always exist co-exist with protective immune responses in AIDS
vaccine recipients. Thus even in animals immunized with a protective
vaccine, a delicate balance exists between protective antiviral immunity
and immune activation capable of driving HIV replication. This balance
must be negotiated to develop an effective HIV vaccine.
Materials and methods
Animals
These studies have been described in detail in previous publications
characterizing the relationship between anti-SIV T cell responses andplasma vRNA levels (Genescà et al., 2008a, 2008b). Brieﬂy, the female
rhesus macaques (Macaca mulatta) used in these studies were housed
at the California National Primate Research Center in accordance with
the American Association for Accreditation of Laboratory Animal Care
standards. The experiments were approved by the Institutional Animal
Care and Use Committee of the University of California, Davis. All
animals were negative for antibodies to HIV-2, SIV, type-D retrovirus,
and simian T cell lymphotropic virus type 1 at the time the study was
initiated.
A total of 35 femaleswere intravenously infectedwith live, virulence-
attenuated SHIV89.6 for six to eight months, as previously described
(Abel et al., 2003). After the6–8months immunizationperiod, at the day
0 time point, nine of these animals were necropsied and a detailed study
of the SIV-speciﬁc T cells responses has been published (Genescà et al.,
2008a). The remaining immunizedmacaques (n=26), were challenged
with pathogenic SIVmac239 by intravaginal inoculation and necropsied
at 3 (n=3), 7 (n=6) or 14 days (n=12) p.c (Genescà et al., 2008a).
Furthermore, 5 immunizedmacaqueswere infused intravenouslywith a
depletingmonoclonal antibody (MAb)directed against CD8α (cM-T807;
50mg/kg bodyweight; Centocor,Malvern, Pa.) on the dayof challenge as
previously described (Genescàet al., 2008a), andnecropsiedat14daysp.
c. Twenty-one naive female macaques were vaginally challenged with
pathogenic SIVmac239andnecropsied at3 (n=3), 7 (n=9)and14days
(n=9) p.c. as unimmunized, control animals.
Animals were assigned to the immunized or unimmunized groups
based on their major histocompatibility complex (MHC) class I
genotype to achieve an even distribution (Genescà et al., 2008a).
Intravaginal SIVmac239 inoculation
The pathogenic SIVmac239 stock used in these studies was
produced in rhesus PBMC as previously described (Miller et al., 1997)
and contained approximately 105 TCID50/ml. The virus challenge
consisted of 2 intravaginal inoculations (separated by 4 h) with 1 ml
of the undiluted SIVmac239 stock.
Tissue collection and sample preparation
Genital tract tissues (cervix, vagina) and genital lymph nodes
(obturator, inguinal and iliac lymph nodes), gut tissues and associated
LNs (colon and mesenteric lymph nodes), distal lymphoid tissues
(axillary lymph nodes and spleen) and blood were collected at the time
of necropsy and analyzed for vRNA levels. Tissues were stored in
RNAlater (Ambion, Austin, TX) and kept at−20°C until preparation of
RNA. Tissue samples were homogenized with a Power Homogenizer
(Power-Gen, Fisher Scientiﬁc) according to the manufacturers protocol.
Total RNAwas isolated using Trizol (Invitrogen, Carlsbad, CA) following
the manufacturers suggested protocol. RNA samples were DNase
treated with DNA-free (Ambion) for 1 h at 37°C. cDNA was prepared
using random hexamer primers (Amersham-Pharmacia Biotech, Inc)
and SuperScript III Reverse Transcriptase (RT) (Invitrogen).
Virological analysis
RT-PCR was used to detect and quantify SIVgag, SIVenv and HIVenv
RNA levels. Samples were tested in replicates of 11 reactions carried
out in 96-well optical plates (Applied Biosystems, Foster City, CA) in a
25 μl reaction volume containing 5 μl cDNA and 20 μl Mastermix
(Applied Biosystems) using the ABI 7900 robotic thermalcycler. All
sequences were ampliﬁed for 2 min at 50°C and 10 min at 95°C
followed by 50 cycles of 15 s at 95°C and 1 min at 60°C. The following
primer pairs and probes were used: SIVgag forward primer 1, 5′–3′
GGGAGA TGG GCG TGA GAA A, reverse primer, CGT TGG GTC GTA GCC
TAA TTT T and probe TCA TCT GCT TTC TTC CCT GAC AAG ACG GA;
SIVenv forward primer GAG ACT AGT TCT TGT ATA GCC CAGGAT AA,
reverse primer CTT TTT AAC CCT GTC ATG TTG AAT TTA C, and probe
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CCT GTC CAA AGG TAT CCT T, reverse primer ATC CAT TGA ATG TCT
TAT TGT TAC ACT TTAG, and probe TCG CAAACC CAG CCGGGACA. The
copy numbers of SIVgag, SIVenv and HIVenv were calculated based on
standard curves for viral gene plasmids spanning a concentration
range from0.1 to 108 copies. The lower detection limit of the assaywas
10 copies. The results were analyzed with SDS 7900 system software
version 2.3 (Applied Biosystems). The results for each sample are
reported as log10 vRNA copies per μg of tissue RNA.
To evaluate the speciﬁcity and determine the background of the
PCR assays for each viral gene, RNA isolated from 11 individual tissues
from 6 rhesus macaques that had never been exposed to SIV were
subjected to ampliﬁcation. There was no ampliﬁcation of SIVgag, or
HIVenv from any of these tissue samples. Thus 50 SIVgag or HIVenv
copies/μg tissue RNA (or 1.7 log10 SIVgag or HIVenv copies/μg tissue
RNA) was used as the cutoff for determining if a tissue sample from an
SIV-inoculated monkey was positive. However, SIVenv was ampliﬁed
from most tissue samples of the uninfected animals. Among these
negative tissues, the colon had the highest average copy number. The
mean SIVenv RNA level in the SIV-negative colon samples plus 2
standard deviations was 132 SIVenv copies/μg tissue RNA. Thus 132
SIVenv copies/μg tissue RNA (or 2.1 log10 SIVenv copies/μg tissue RNA)
was used as the cutoff for determining if a tissue sample from an SIV-
inoculated animal was positive for SIVenv RNA.
Enumeration of SIV-infected cells in tissue sections
The number of SIV RNA+ cells in 6-μm-thick sections of parafﬁn-
embedded tissues was determined by in situ hybridization (ISH) using
eight radio-labeled (S35) anti-sense riboprobes (0.7 to 1.5 kb) spanning
the whole SIVmac239 genome as previously described (Hu, Gardner,
and Miller, 2000; Hu et al., 1998). It should be noted that it was not
possible to distinguish between cells infected with the vaccine virus,
SHIV89.6, and cells infected with the challenge virus, SIVmac239.
Negative controls for ISH were slides with SIV-negative tissue sections
and slides with SIV-positive tissue sections but hybridized to SIV sense
probes. To quantify the number of SIV-infected cells, the slides were
counterstained with hematoxylin (Vector) after the ISH labeling. The
slides were viewed on a Axiophot microscope and photographed with
an AxioCam camera (Carl Zeiss). SIV-positive cells were counted in
randomly chosen ﬁelds, and the frequency of SIV-positive cells as the
number of SIV RNA positive cells per ten low power ﬁelds (10×
objective) in sections of cervix and vagina or SIV RNA+ cells/mm2 in
axillary LN sections was calculated (not shown).
Statistical analysis
GraphPad Prism version 5 for Apple OSX10.4 (GraphPad Software,
San Diego California USA) and Macintosh G5 computers (Apple Inc.,
Cupertino CA)were used for all analyses. The p values for comparisons
of mean tissue and plasma vRNA levels in each animal group were
evaluated by unpaired one-tailed T-test. Differences in the mean vRNA
levels in tissues among the different animal groups were tested with a
one-way ANOVA and Bonferroni's multiple comparison post-hoc test.
Analysis of vRNA levels among all tissues at each time point was done
using a one-way ANOVA with Dunn's multiple comparison post test.
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